Member Info for Bella6532

BV....and Janet Munro's (Head Program Innovation, Global Drug Development at Novartis) 'Best is still to come ' comment on Linkedin with a fingers crossed emoji was quite a nod to Avactas AVA6000 data.

BV...you're forgetting the long terms contacts the likes of CC have and our Partners. Pharma is like any other big industry/business. Contacts are key to breaking the herd mentality. They all jump in on what they think is going to be the next big 'must have'. Avacta and their current partners have to now work those contacts and convince one or more Pharma (not necessarily biggies) to take up one or more of the PreCision pipeline products. They can only do this with data and FDA approval but the contacts can now be warmed up. PreCision right now is a leap of faith for most companies but that will change as they have access to the hard data.

If you look at the stories behind successful ground breaking innovative products/businesses, they too hit brick walls.

ARM was just such a company and when they finally broke through the wall they were still able to build a very successful business on their own and it was some years before they sold out. Their business model was based on a Licenced out Platform.

Shorters or sellers market right now with the prospect of new shares incoming next week and easy pickings if PI's have stop losses in place...

If Avacta really wanted to help their real 'investors' they would cover this qrtly with cash...they have plenty and it would send a clear message to the market traders.

FDA approval...2W data combined with ongoing data collected from 3W patients still being dosed (which may be admisable) should help to speed things up.

As there's othing more we can say or do about the trials right now apart from sit and wait for news, we do have the Prelims coming up next week hopefully with the lifting of any news blackout/closed period which may come with more insights for us to bicker over for a few more days/weeks.

Now who are the European chappies...goodies or badies...what are they really bringing to the table...out or nowt???

DX...bottom position on Avacta website/very much pushed into the background...why? Will we get some answers next week.

Sentiment...yes...the markets are not convinced yet...they like to see profits or the sniff of same.

So far we are only in P1 trials...not quite good enough for the markets...they want to see FDA approval.

DX...too much background debt right now...they want to see more upswing in income v debt and like many PI's the true synergy has not really been explained/realised. New products containing affimers flying off the shelves might just do the trick.

Hey ho...not long to go...

Icecool...'FDA approved oncology drugs are worth a fortune, many multiples of our current mkt cap alone. Exciting summer ahead imo.'...

Yep and June/July is where the starting line will be drawn...

In the meantime we have Prelims to look forward to...last year was 25 April...so next week we should have at least two RNS's ...Prelims and Qrtly issue of Equity/Cash...go on Avacta put the cat amonsgt them and splash the cash this time...

Now was AS talking about the Closed Period when he said he couldn't discuss non-AVA6000 matters or was he referring to a News blackout connected to the REX offering...either way, there could be some more sweetners to come within the Prelims notes...

Yes and might make Heights think twice about pre-selling...

Does " don't worry about funding" seem like a true statement.

It is now...however, there are still questions about the DX website section now being just a footer entry heading on the Avacta website.

We do need the final jigsaw pieces spelling out once closed period is over...

There is also the Derivative element whcih was showing as a credit at last valuation. It will be interesting to see how this pans out in the upcoming financials.

'The bond agreement contains embedded derivatives in conjunction with an ordinary host debt liability. As a result, the convertible bonds are shown in the Consolidated Statement of Financial Position in two separate components, being 'Convertible bond - debt' and 'Convertible bond - derivative'. The derivative element has been measured at fair value using a Monte-Carlo option pricing model, which estimates the fair value based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the bondholders.

The derivative element, taking into account the amortisations and early redemption, was revalued as at 30 June 2023 at £28.90 million (30 June 2022: £nil; 31 December 2022: £39.10 million), which has resulted in a credit within the period of £5.86 million.

The debt element of the bond has reduced from £18.73 million at 31 December 2022 to £15.68 million at 30 June 2023 (30 June 2022: £nil), with an associated non-cash interest expense of £6.85 million.'

cje306...at this point I really don't know...just need to see the next payment amount/shares to see what the conversion price has been recalculated at. Like you I don't think the consequences of the Bond are as bad as some may think and the upcoming financials should give us a better idea of company cash burn, DX income v loss status etc etc...

This year is going to be really interesting within the EU with the upcoming elections and of coure UK elections.

Gje306...we also have the ability to pay in cash not shares and DX might, if profits exceed expectations, be in a position to cough up the readies...

There is also the possibility of an upfront deal and/or milestone payments coming into TX before your 2 years are up which again could generate the cash for the bond payments.

The amount of cash Avacta now has there's also the bit of interest earned in intitally which will help cashflow too...every bit helps eh!

My calculations are:

As a result of the Offer Price being less than 95 per cent. of the VWAP in the five-day trading period prior to the announcement of the Placing, the Direct Subscription and the REX Offer, the conversion price (118.75 pence) and the reset floor price (95 pence) will be recalculated by the calculation agent using an adjustment factor calculation as follows:

1. the adjustment factor will be (A+B)/(A+C), where:

1. A = number of Shares in issue immediately before the date of first public announcement of the terms (the "Pricing Date") of the Bookbuild; ......... 288,215,722

2. B = aggregate gross proceeds of the Bookbuild divided by the Current Market Price ("CMP") on the Pricing Date of the Bookbuild, where CMP on the Pricing Date = arithmetic average of the five daily VWAPs immediately preceding the Pricing Date; and .............37,971,582 based on 0.8764 average

3. C = number of Shares comprised in the Bookbuild.........62,296,557

Gje306...what conversion price did you come up with for the recalculation as detailed in the Placing RNS? I get 0.93 but not sure that's correct...

As a result of the Offer Price being less than 95 per cent. of the VWAP in the five-day trading period prior to the announcement of the Placing, the Direct Subscription and the REX Offer, the conversion price (118.75 pence) and the reset floor price (95 pence) will be recalculated by the calculation agent using an adjustment factor calculation as follows:

1. the adjustment factor will be (A+B)/(A+C), where:

1. A = number of Shares in issue immediately before the date of first public announcement of the terms (the "Pricing Date") of the Bookbuild;

2. B = aggregate gross proceeds of the Bookbuild divided by the Current Market Price ("CMP") on the Pricing Date of the Bookbuild, where CMP on the Pricing Date = arithmetic average of the five daily VWAPs immediately preceding the Pricing Date; and

3. C = number of Shares comprised in the Bookbuild.

The principal remaining under the Bonds was reduced by a further £2.55 million to £38.25 million on 22 January 2024 following the fifth quarterly amortisation.

Rock on June...

B2HS2L...when it comes to being on the trial he will only get what is given to him...if he gets to a point where the trial cannot administer any further doses, for whatever reason, I'm sure he will be coached accordingly. Perhaps there is provision in the 2 weekly to take on 1a Cohorts or perhaps they intend to move them on to Phase 2 which would seem the likely senario. Safety having been no problem in all 1a Cohorts with efficacy already observed and to be continued in Phase 2 with patients moved onto the new Phase 2 dose...perhaps.

BV...'that patient has two choices: continue being dosed at the 160mg/mm² level he has been on;' Oops sorry missed that...

For anyone with cancer...the smallest of improvements are huge. The fact that he can still receive doses of Dox with virtually no side effects is huge in itself. It's often the damage done by chemo or at least the horrendous side effects that either lead to death or patients giving up on their treatments. All these patients were end of lifers and now there is potentially some hope for at least some of them, if not all.

For the life of me I cannot understand why some are so negative on here...pure self interest rather than seeing the bigger picture. As I've said before, we are early stage...very early stage...and if you can't afford to wait another couple of years then you really should not be investing in AIM listed companies.

BV..' patients remain on cohort dosage (on trial) UNTIL DISEASE PROGRESSION.' Wasn't he on one of the earlier Cohorts...if so his dosage would be somewhat lower.

And what about thoses itsy bitsy cancer cells that may have been undetected by the scans yet lurking and growing undetected...if they have now been utralised too then that's were the benefit lies...plus aif the tumour has reduced is size it may become operable whereas it may not have been before...all unknowns for us right now.

Nanomat...AVA6000 and the pipeline are just still dreams right now. They are not income generating, apart frim the odd few quid we get now and again from desls already in place. DX is income generating...OK not profitable yet but if you read the financials you'll see the forecasts and they are very positive. DX gives Avacta cash flow and a chest of cash...couple that with being able to add the affimer tech into the DX mix and you add value. TX is still a gamble...DX was a gamble at the time of the bond raise but now it's not...it had asset to back the loan and that asset is 3 sectors combjned DX + 2 companies...plus everything else they bring to the table for not only DX but TX too...customers and suppliers should never be underestimated...

Oh and for those not familiar with how diagnostics are moving...home testing, private company testing, doctor surgery testing is becoming more common place. Not just for the likes of covid but a range of all sorts of more common ailments.

Oh and I doubt the decision to go for a fully funded DX M&A strategy was solely AS...this would have been a Board decision.

Very short sighted to not see the benefits of the two acquisitions. I don't like the bond deal but for the amount raised and dilution over an extended period rather in one go and fact there's cash left iver to help create cash flow was IMO a necessary evil.

Being a distributor is easy cash flow. The overheads are small yet both purchases have brought into the company a new customer base and manufacturing contacts etc. If you think the affimer tech has merit DX can now work on getting affimer tech into a variety of products with all the customer awareness that will naturally go with sales discussions etc...

Profit forecasts look fairly good too.

Now those on here who know better...what would you have done...simply raise cash through the markets and get nowt else for it except dilusion....